analyst
OL
NASDAQ · OLMA
Olema Pharmaceuticals, Inc.
Healthcare · Biotechnology
$9.78
Down-$0.51 (-4.96%)
Updated Sep 16, 2026, 10:57 AM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.17B
- P/E ratio
- -18.05
- Dividend yield
- 0.00%
- 52-week range
- $6.65 – $36.26
- Volume
- 1.73M
- Avg. volume
- 3.41M
Price performance
OLMA price history
1M range · 0 trading sessions · Daily adjusted prices
OLMA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OLMA news
The latest Smart Investors Daily articles mentioning OLMA.
Stock researchCompany · Overview
OLMA research
Overview
Company profile and research snapshot.
Company profile
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $42.80
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | Stifel | Buy | — |
| Aug 13, 2026 | JP Morgan | Overweight | — |
| Aug 11, 2026 | Citigroup | Buy | — |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| May 13, 2026 | Guggenheim | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.